FY2025 EPS Estimates for AxoGen Cut by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of AxoGen in a report issued on Monday, June 2nd. Cantor Fitzgerald analyst R. Osborn now anticipates that the medical equipment provider will post earnings per share of ($0.06) for the year, down from their previous forecast of $0.02. Cantor Fitzgerald currently has a "Overweight" rating and a $24.00 price objective on the stock. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

AXGN has been the topic of a number of other reports. Lake Street Capital began coverage on AxoGen in a research note on Monday, March 17th. They issued a "buy" rating and a $30.00 price target on the stock. Canaccord Genuity Group decreased their target price on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $22.20.

AxoGen Trading Down 0.9%

Shares of NASDAQ:AXGN traded down $0.10 during midday trading on Wednesday, reaching $10.80. The company's stock had a trading volume of 505,686 shares, compared to its average volume of 469,195. The firm has a market cap of $491.88 million, a price-to-earnings ratio of -33.75 and a beta of 1.19. The business has a 50 day moving average price of $14.34 and a 200 day moving average price of $16.00. AxoGen has a 1 year low of $6.59 and a 1 year high of $21.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67.

Hedge Funds Weigh In On AxoGen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in shares of AxoGen by 34.4% during the fourth quarter. SG Americas Securities LLC now owns 21,763 shares of the medical equipment provider's stock valued at $359,000 after purchasing an additional 5,576 shares during the period. R Squared Ltd purchased a new position in shares of AxoGen in the fourth quarter valued at $30,000. Calamos Advisors LLC acquired a new stake in AxoGen during the 4th quarter valued at $523,000. Legato Capital Management LLC increased its stake in AxoGen by 42.8% during the 4th quarter. Legato Capital Management LLC now owns 34,524 shares of the medical equipment provider's stock worth $569,000 after buying an additional 10,344 shares during the period. Finally, Rhumbline Advisers lifted its holdings in AxoGen by 2.7% in the 4th quarter. Rhumbline Advisers now owns 58,232 shares of the medical equipment provider's stock worth $960,000 after buying an additional 1,521 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Joseph A. Tyndall sold 20,062 shares of the company's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $11.20, for a total value of $224,694.40. Following the completion of the sale, the director now owns 15,345 shares of the company's stock, valued at $171,864. This represents a 56.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares of the company's stock, valued at approximately $3,810,835. This trade represents a 6.49% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.78% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.